MAGEC2 and breast carcinoma: MAGEC2, has been shown to be aberrantly expressed in squamous cell carcinomas, melanomas, sarcomas, myelomas, hepatocellular carcinomas, lung carcinoma, prostate adenocarcinoma, and breast carcinoma (20–22).